Research programme: hypoxia-inducible factor 1 alpha inhibitors - BTGAlternative Names: BTG 6228
Latest Information Update: 21 Mar 2014
At a glance
- Originator Bionaut Pharmaceuticals
- Developer BTG
- Mechanism of Action Hypoxia-inducible factor-1 alpha inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 29 May 2007 Preclinical trials in Solid tumours in United Kingdom (unspecified route)